Bristol‑Myers Squibb reported fourth‑quarter and full‑year 2025 results on February 5 2026, posting revenue of $12.5 billion—an increase of 1% year‑over‑year—and adjusted earnings per share of $1.26, beating consensus estimates of $1.11–$1.13 by roughly $0.15 per share. The company’s growth portfolio, which now accounts for nearly 60% of total revenue, grew 15% to $7.4 billion, while legacy portfolio sales fell 15% to $5.1 billion, reflecting ongoing patent‑cliff erosion.
The revenue beat was driven by robust sales of Opdivo, Breyanzi, and Reblozyl. Opdivo revenue rose 7% to $2.7 billion, Breyanzi surged 47%, and Reblozyl grew 21%. These gains offset the decline in legacy products and helped lift overall top‑line growth. The company’s productivity initiative delivered $1 billion in cost savings in 2025, which helped cushion the impact of a 2.1 percentage‑point drop in non‑GAAP gross margin from 74.0% to 71.9% caused by a shift toward lower‑margin growth products.
Bristol‑Myers Squibb’s adjusted EPS beat was largely a result of disciplined cost control and the productivity initiative, which reduced operating expenses while the company maintained pricing power in its high‑margin growth drugs. The company’s margin compression was modest, reflecting the mix shift toward higher‑volume, lower‑margin products, but the cost savings program helped preserve profitability. The company’s prior‑year Q4 EPS of $1.67 provides context for the current $1.26 figure, indicating a modest decline in earnings per share as legacy sales continue to wane.
Management guided 2026 revenue to $46.0 billion–$47.5 billion, well above the consensus of $44.2 billion, and adjusted EPS to $6.05–$6.35 versus a consensus of $6.02. The company also raised its dividend to $0.63 per share, marking the 17th consecutive annual increase. CEO Christopher Boerner said the company is “focused on execution” and that the 2026 outlook is “data‑rich” with multiple pivotal pipeline readouts expected later in the year.
The market reacted positively, with the stock trading up between 1.75% and 3.77% in pre‑market trading. Analysts highlighted the earnings beat and the upward revision of guidance as key drivers of the rally, noting that the company’s ability to grow its high‑margin portfolio while managing legacy decline signals strong execution and confidence in its long‑term strategy.
Headwinds remain as patent cliffs continue to erode legacy sales, and Eliquis is expected to see a step‑down in 2027. However, tailwinds include the growth portfolio’s acceleration, new product launches such as Cobenfy and Qvantik, and a robust pipeline that is expected to generate additional revenue in the coming years. The company’s cost‑saving program and strategic focus on high‑return investments position it well to navigate these challenges while sustaining growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.